O‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review)
Oncology Reports · 2025
DOI: 10.3892/or.2025.8952 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Reports, 2025. Verfasst von Purin Charoensuksai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine and Health Informatics, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand. Hauptthemen laut MEDLINE: Cholangiocarcinoma, N-Acetylglucosaminyltransferases, Bile Duct Neoplasms. Die Arbeit nennt 197 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aberrant O‑GlcNAcylation and the upregulation of O‑GlcNAc transferase (OGT) are key contributors to cancer pathogenesis and progression, driving hyperproliferative states and metastatic phenotypes. Targeting OGT may suppress cancer progression, positioning OGT and O‑GlcNAc signaling as compelling targets in cancer research. Cholangiocarcinoma (CCA), a rare yet highly aggressive malignancy of the bile duct system, represents a clinical challenge, underscored by its rising global mortality, poor survival outcomes and high recurrence rate, despite advances in awareness, diagnostics and therapeutic strategies. Consequently, there is need for novel therapeutic modalities. Hyperactive O‑GlcNAcylation and upregulation of OGT are observed in CCA, therefore, targeting protein O‑GlcNAcylation may have clinical potential. The present review aimed to summarize the impact of O‑GlcNAcylation on CCA and CCA‑relevant hallmarks of cancer including cell proliferation, metastasis, metabolic reprogramming, angiogenesis, programmed cell death and tumor‑associated inflammation. In areas where direct evidence in CCA is limited, insights from other gastrointestinal tract cancers may identify potential mechanistic connections, offering a broader context to guide future investigation. Furthermore, the viability of OGT and O‑GlcNAcylation as therapeutic targets is discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine and Health Informatics, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand.
- Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Zitieren
APA
Charoensuksai, P., & Jirawatnotai, S. (2025). O‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review). Oncology Reports. https://doi.org/10.3892/or.2025.8952
Vancouver
Charoensuksai P, Jirawatnotai S. O‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review). Oncology Reports. 2025. doi:10.3892/or.2025.8952
BibTeX
@article{Charoensuksai2025,
author = {Charoensuksai, Purin and Jirawatnotai, Siwanon},
title = {O‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review)},
journal = {Oncology Reports},
year = {2025},
doi = {10.3892/or.2025.8952}
}
EUVIMED